Addendum
Esketamine (depression, acute treatment) - Addendum to Commission A21-25
Report documents
-
Addendum
Esketamine (depression, acute treatment) - Addendum to Commission A21-25
Dossier assessment
Indication:
Adult patients with a moderate to severe episode of major depressive disorder, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency
Result of dossier assessment:
Added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021-08-19 A G-BA decision was published.
Project details
- Project no.
- A21-91
- Commission
- Commission awarded on 06.07.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed